CAPLYTA tv commercials
TV spots
TV commercials CAPLYTA
CAPLYTA TV spot 'Dawn' opens with a magnificently lit early morning shot of a hilly landscape. The ad focuses on a woman, Emily, who is seen walking through the scenic beauty. The voiceover explains that Emily has struggled with schizophrenia, but now she's found something that allows her to enjoy m...
Caplyta TV Spot, 'Let in the Lyte Part II' is an advertisement featuring the latest treatment for schizophrenia. This treatment aims to provide relief to patients dealing with the condition's debilitating symptoms.The TV spot showcases the struggles that people who are dealing with schizophrenia oft...
CAPLYTA TV Spot, 'Let In the Lyte' is a commercial advertisement created to promote a new medication that is used in the treatment of schizophrenia in adults. The 30-second commercial features a young woman experiencing the effects of schizophrenia, but with the help of CAPLYTA, she is able to manag...
Title: CAPLYTA TV Spot - 'Real Progress': "Life is a journey, filled with ups and downs. But what if there was a new way to navigate those difficult moments?": "Meet Sarah. She's been struggling with the challenges of everyday life, feeling overwhelmed, and unable to find joy in the things she used...
Title: CAPLYTA TV Spot: 'See Progress Differently': "Are you tired of feeling trapped by your mental health condition?": "Introducing Caplyta, a revolutionary new treatment that allows you to see progress differently.": "With Caplyta, the world starts to come alive again. Colors become vivid, sounds...
Actors
Actors who starred in CAPLYTA commercials
What kind of company is CAPLYTA?
What is CAPLYTA?
CAPLYTA is a brand name for the drug lumateperone, which is an atypical antipsychotic medication indicated for the treatment of schizophrenia in adults. It is manufactured by Intra-Cellular Therapies, a biopharmaceutical company focused on developing innovative therapies for neuropsychiatric and neurodegenerative diseases.
What is Intra-Cellular Therapies?
Intra-Cellular Therapies is a publicly traded biopharmaceutical company headquartered in New York City. The company was founded in 2002 and is dedicated to developing innovative treatments for neuropsychiatric and neurodegenerative diseases that significantly affect cognitive and functional abilities. Intra-Cellular Therapies' pipeline of product candidates is based on Nobel Prize-winning research and is focused on addressing significant unmet needs in the treatment of cognitive and behavioral disorders. CAPLYTA is the company's lead product and was approved by the U.S. Food and Drug Administration (FDA) in December 2019 for the treatment of adults with schizophrenia.
What are the benefits of CAPLYTA?
CAPLYTA is a selective and concurrent modulator of neurotransmitter systems that are frequently dysregulated in multiple neuropsychiatric disorders , including schizophrenia. Its mechanism of action is thought to involve blocking the serotonin 5-HT2A receptor and modulating dopamine signaling in the brain's mesolimbic pathway. Clinical data has demonstrated that CAPLYTA has significant antipsychotic effects and can improve overall symptom severity in adults with schizophrenia. CAPLYTA is also associated with fewer incidences of extrapyramidal side effects, such as movement disorders, compared to other antipsychotic medications.
What are some potential side effects of CAPLYTA?
Common side effects of CAPLYTA include sleepiness, dry mouth, and weight gain. Other possible side effects include dizziness, restlessness, and muscle contractions. Like all antipsychotic medications, CAPLYTA has the potential to cause serious and life-threatening side effects, such as tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes. Patients should discuss any concerns about possible side effects with their healthcare provider.
Conclusion
Intra-Cellular Therapies' CAPLYTA is an important product in the treatment of schizophrenia, a complex and often debilitating neuropsychiatric condition. The company is committed to bringing innovative therapies to market that can address significant unmet medical needs and improve patient outcomes.
